Vishay Precision Group reported net earnings attributable to VPG stockholders of $0.8 million, or $0.06 per diluted share, for the fourth fiscal quarter ended December 31, 2024. This compares to $4.2 million, or $0.31 per diluted share, in the fourth fiscal quarter of 2023. Adjusted net earnings for the quarter were $0.4 million, or $0.03 per diluted share.
For the full fiscal year 2024, net earnings attributable to VPG stockholders were $9.9 million, or $0.74 per diluted share, compared to $25.7 million, or $1.88 per diluted share, in fiscal year 2023. Adjusted net earnings for the full year were $12.7 million, or $0.95 per diluted share. The company faced macro and cyclical headwinds throughout 2024.
Total orders in the fourth fiscal quarter were $72.4 million, representing a 5.5% sequential growth and a book-to-bill ratio of 1.00. This marked the first fiscal quarter of sequential bookings growth in six quarters, driven by the Sensors and Weighing Solutions segments. The integration of Nokra, acquired on September 30, 2024, is proceeding as planned.
The Sensors segment revenue was $25.8 million, a 24.8% year-over-year decrease, with a gross profit margin of 32.0%. Weighing Solutions revenue was $25.7 million, down 15.4% year-over-year, with a gross profit margin of 34.1%. Measurement Systems revenue was $21.2 million, a 14.8% year-over-year decrease, with a gross profit margin of 50.9%.
For the first fiscal quarter of 2025, VPG expects net revenues to be in the range of $70 million to $76 million. The company continues to focus on its business development pipeline, including projects in industrial and medical robotics, data center, and telecommunications applications. Management emphasized ongoing cost-savings initiatives to deliver operating leverage as revenues strengthen.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.